Protein s as cofactor for TFPI

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 12, 2009, Pages 2015-2020

  Hackeng, Tilman M ^a   Rosing, Jan ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anticoagulant mechanisms; Extrinsic pathway; Proteins; TFPI; Thrombin generation

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; PHOSPHOLIPID; PROCOAGULANT; PROTEIN S; PROTHROMBIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; BINDING SITE; BLOOD CLOTTING; COMPETITION; DOWN REGULATION; HEMOSTASIS; NEGATIVE FEEDBACK; OBSERVATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PURIFICATION; REVIEW;

ANTICOAGULANTS; BLOOD COAGULATION; FACTOR VIIA; FACTOR XA; HUMANS; KINETICS; LIPOPROTEINS; MODELS, BIOLOGICAL; PROTEIN S; PROTEIN STRUCTURE, QUATERNARY;

EID: 73849136742     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.177436     Document Type: Review

References (49)

1. Dahlbäck B. The tale of protein S and C4b-binding protein, a story of affection. Thromb Haemost. 2007;98:90-96.
2. Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Varadi K, Schwarz HP, Tans G. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270: 27852-27858.
3. O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood. 2000;95:1714-1720.
4. Maurissen LF, Thomassen MC, Nicolaes GA, Dahlbäck B, Tans G, Rosing J, Hackeng TM. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood. 2008;111:3034-3041.
5. Castoldi E, Hackeng TM. Regulation of coagulation by protein S. Curr Opin Hematol. 2008;15:529-536.
6. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med. 1984;311: 1525-1528.
7. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984;64: 1297-1300.
8. García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis of protein S deficiency. Thromb Haemost. 2007;98:543-556.
9. Vantveer C, Hackeng TM, Biesbroeck D, Sixma JJ, Bouma BN. Increased prothrombin activation in protein S-deficient plasma under flow conditions on endothelial-cell matrix-an independent anticoagulant function of protein-S in plasma. Blood. 1995;85:1815-1821.
10. Seré KM, Rosing J, Hackeng TM. Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance. Blood. 2004;104:3624-3630.
11. Hackeng TM, Seré KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 2006;103:3106-3111.
12. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem. 1993;268: 2872-2877.
13. Hackeng TM, van't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem. 1994; 269:21051-21058.
14. Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A. 1994;91:2728-2732
15. van't Veer C, Butenas S, Golden NJ, Mann KG. Regulation of prothrom-binase activity by protein S. Thromb Haemost. 1999;82:80-87.
16. Heeb MJ, Schuck P, Xu X. Protein S multimers and monomers each have direct anticoagulant activity. J Thromb Haemost. 2006;4: 385-391.
17. Sere KM, Janssen MP, Willems GM, Tans G, Rosing J, Hackeng TM. Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. Biochemistry. 2001;40: 8852-8860.
18. Sere KM, Willems GM, Rosing J, Hackeng TM. Protein S multimers are generated in vitro and affect protein S structure-function analyses. Semin Hematol. 2006;43:S111-S120.
19. Mitchell CA, Kelemen SM, Salem HH. The anticoagulant properties of a modified form of protein S. Thromb Haemost. 1988;60:298-304
20. vanWijnen M, Stam JG, vantVeer C, Meijers JCM, Reitsma PH, Bertina RM, Bouma BN. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost. 1996;76:397-403.
21. Heeb MJ, Radtke KP, Fernandez JA, Tonnu L. Plasma contains protein S monomers and multimers with similar direct anticoagulant activity. J Thromb Haemost. 2006;4:2215-2222.
22. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a CDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of 3 tandem Kunitz-type inhibitory domains. J Biol Chem. 1988;263:6001-6004.
23. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor-evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A. 1990;87:8869-8873.
24. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989; 338:518-520.
25. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinol. 1993;4:661-669. (Pubitemid 23343388)
26. Broze GJ, Lange GW, Duffin KL, Macphail L. Heterogeneity of Plasma Tissue Factor Pathway Inhibitor. Blood Coagul Fibrinol. 1994;5: 551-559.
27. Hackeng TM, Maurissen LFA, Castoldi E, Rosing J. Regulation of TFPI function by protein S. J Thromb Haemost. 2009;7:165-168.
28. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor-VII-tissue factor complex also inhibits factor Xa-insight into its possible mechanism of action. Blood. 1988;71:335-343.
29. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry. 1991;30:10371-10376.
30. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood. 1992;79:2004-2010.
31. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991;78:387-393.
32. Huang ZF, Wun TC, Broze GJ. Kinetics of factor-Xa inhibition by tissue factor pathway Inhibitor. J Biol Chem. 1993;268:26950-26955.
33. Ndonwi M, Broze GJ Jr. Protein S enhances the TFPI inhibition of factor Xa but not its inhibition of factor VIIa/tissue factor. J Thromb Haemost. In press.
34. Vantveer C, Hackeng TM, Delahaye C, Sixma JJ, Bouma BN. Activated factor-X and thrombin formation triggered by tissue factor on endotheli-al-cell matrix in a flow model-effect of the tissue factor pathway inhibitor. Blood. 1994;84:1132-1142.
35. Hackeng TM, Hessing M, van't Veer C, Meijer-Huizinga F, Meijers JC, de Groot PG, van Mourik JA, Bouma BN. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem. 1993;268:3993-4000.
36. Stenberg Y, Muranyi A, Steen C, Thulin E, Drakenberg T, Stenflo J. EGF-like module pair 3-4 in vitamin K-dependent protein S: Modulation of calcium affinity of module 4 by module 3, and interaction with factor X. J Mol Biol. 1999;293:653-665.
37. Yegneswaran S, Hackeng TM, Dawson PE, Griffin JH. The thrombin-sensitive region of protein S mediates phospholipid-dependent interaction with factor Xa. J Biol Chem. 2008;283:33046-33052.
38. Lockett JM, Mast AE. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor. Biochemistry. 2002;41:4989-4997.
39. Dahm AE, Sandset PM, Rosendaal FR. The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost. 2008;6:393-395.
40. Broze GJ, Girard TJ, Novotny WF. Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor. Biochemistry. 1990;29: 7539-7546.
41. Nicolaes GA, Thomassen MC, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibri-nolysis. 1997;8:28-38.
42. De Visser MCH, Vlieg AV, Tans G, Rosing J, Dahm AEA, Sandset PM, Rosendaal FR, Bertina RM. Determinants of the APTT-and ETP-based APC sensitivity tests. J Thromb Haemost. 2005;3:1488-1494.
43. Dielis AWJH, Castoldi E, Spronk HMH, Van Oerle R, Hamulyak K, Ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008;6:125-131.
44. van Wijnen M, van't Veer C, Meijers JC, Bertina RM, Bouma BN. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. Thromb Haemost. 1998;80:930-935.
45. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood. 1996;87: 1845-1850.
46. Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem. 1988;263:14884-14890.
47. Brufatto N, Nesheim ME. The use of prothrombin(S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by anti-thrombin during prothrombin activation. J Biol Chem. 2001;276: 17663-17671.
48. Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U. Molar antithrombin concentration in normal human plasma. Haemostasis. 1983; 13:363-368.
49. Gruber A, Griffin JH. Direct detection of activated protein-C in blood from human-subjects. Blood. 1992;79:2340-2348.